NASDAQ:PTCT PTC Therapeutics Q3 2026 Earnings Date & Estimates $62.25 -0.37 (-0.59%) As of 09:36 AM Eastern This is a fair market value price provided by Massive. Learn more. PTC Therapeutics is estimated to report Q3 2026 earnings on Thursday, October 29, 2026, after market closes. The conference call is scheduled for 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateOctober 29, 2026TimeAfter Market ClosesConference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from PTC Therapeutics in Q3 2026PTC Therapeutics is expected to post earnings of $0.2071 per share on revenue of $304.60 million. In the same quarter a year earlier PTC Therapeutics reported $0.20 per share on revenue of $211.01 million. PTC Therapeutics last reported on July 30, 2026, posting $0.92 per share and beating the $0.2363 consensus estimate. PTC Therapeutics has beaten the consensus EPS estimate in 6 of its last 8 quarters.Consensus EstimatesConsensus EPS$0.2071Expected Revenue$304.60 millionPrior-Year EPS$0.20Prior-Year Revenue$211.01 millionExpected EPS Growth+3.6%Expected Revenue Growth+44.4%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS$0.92 (Beat by +$0.6837)Last Quarter Revenue$360.52 millionEPS Beat Rate6 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report PTC Therapeutics Q3 2026 Earnings FAQ When does PTC Therapeutics report Q3 2026 earnings? PTC Therapeutics (NASDAQ:PTCT) is estimated to report Q3 2026 earnings on Thursday, October 29, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is PTC Therapeutics' Q3 2026 earnings call? PTC Therapeutics' Q3 2026 earnings conference call is scheduled for Thursday, October 29, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for PTC Therapeutics? Analysts expect PTC Therapeutics to post earnings of $0.2071 per share for Q3 2026. How much revenue is PTC Therapeutics expected to report? The consensus revenue estimate for PTC Therapeutics is $304.60 million for Q3 2026. PTC Therapeutics Earnings HeadlinesTruist Financial Initiates Coverage on PTC Therapeutics (NASDAQ:PTCT)October 18, 2026 | americanbankingnews.comComparing Spyre Therapeutics (NASDAQ:SYRE) & PTC Therapeutics (NASDAQ:PTCT)October 16, 2026 | americanbankingnews.comThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before they ever place a trade. This free guide from Base Camp Trading takes a different approach, starting with the basics and showing you exactly how options work, why traders use them, and how they fit into a simple trading plan.October 22 at 1:00 AM | Base Camp Trading (Ad)UBS Adjusts Price Target on PTC Therapeutics to $90 From $80, Maintains Buy RatingOctober 15, 2026 | marketscreener.comMPTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026October 15, 2026 | prnewswire.comPTC Therapeutics (NASDAQ:PTCT) Director Sells $158,475.00 in StockOctober 12, 2026 | americanbankingnews.comSee More PTC Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like PTC Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PTC Therapeutics and other key companies, straight to your email. Email Address About PTC TherapeuticsPTC Therapeutics (NASDAQ:PTCT) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Its research programs include small-molecule treatments, gene therapies and other approaches designed to address conditions with limited or no available treatment options. The company’s commercial portfolio has included Emflaza (deflazacort), a corticosteroid approved in the United States to treat Duchenne muscular dystrophy, and Upstaza (eladocagene exuparvovec), a gene therapy authorized in the European Union for aromatic L-amino acid decarboxylase deficiency. PTC also developed Translarna (ataluren) for certain patients with nonsense mutation Duchenne muscular dystrophy; the product has been available in some international markets, although its regulatory status has changed over time. PTC Therapeutics was founded in 1998 and is headquartered in Warren, New Jersey. The company serves patients and healthcare providers in the United States and international markets through its own commercial operations and partnerships. Its development pipeline has historically focused on rare neurological, metabolic and genetic disorders.View PTC Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles SpaceX Earnings Launch: High Margins Fund AI AmbitionsBoarding Now—GE Aerospace's Earnings Beat Comes With a CatchGM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?Synchrony Aces The Quarter As Credit Fears FadeHigher Rates Are Sending Investors to These 3 Dividend KingsServiceNow Orchestrates AI's Next Act—Can Earnings Deliver?Are RTX Corporation and Northrop Grumman Ready to Break Out? Upcoming Earnings ENI (10/23/2026)SLB (10/23/2026)American Express (10/23/2026)Infosys (10/23/2026)Verizon Communications (10/26/2026)Nucor (10/26/2026)Public Storage (10/26/2026)Welltower (10/26/2026)Cadence Design Systems (10/26/2026)Hilton Worldwide (10/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
